Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

for the treatment of overactive bladder (OAB).This is the first time that CTAF has addressed this topic.

The standard treatments for overactive bladder include lifestyle changes, bladder training, pelvic floor muscle training and anticholinergic (anti-muscarinic) drugs. Additional treatments for some ...

Antimuscarinic drugs are the first-line treatment for overactive bladder. However, traditional formulations are associated with a number of adverse effects, most notably dry mouth. A study ...

The Food and Drug Administration (FDA) has approved Gemtesa ® (vibegron) for the treatment of overactive bladder (OAB ... is an important milestone for the men with unresolved symptoms of ...

Urination problems affect millions of men worldwide, often developing so gradually that many dismiss early warning signs.

Mostly, older women are more prone to an overactive bladder usually, but a recent representative cohort study indicates the number of men with overactive bladder is significantly on the rise.

An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...